In Re PSS World Medical, Inc. Securities Litigation

250 F. Supp. 2d 1335, 2002 U.S. Dist. LEXIS 14887, 2002 WL 32054710
CourtDistrict Court, M.D. Florida
DecidedAugust 1, 2002
Docket301CV795J16TEM
StatusPublished
Cited by9 cases

This text of 250 F. Supp. 2d 1335 (In Re PSS World Medical, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re PSS World Medical, Inc. Securities Litigation, 250 F. Supp. 2d 1335, 2002 U.S. Dist. LEXIS 14887, 2002 WL 32054710 (M.D. Fla. 2002).

Opinion

ORDER

MOORE, District Judge.

Before the Court is Defendants’ Motion to Dismiss Amended Class Action Complaint and Incorporated Memorandum of Law (Dkt.36). Plaintiffs filed a Memorandum of Law in Opposition to Defendants’ Motion to Dismiss Class Action Complaint (Dkt.40). The Court heard oral arguments from the parties concerning the Defendants’ Motion on July 12, 2002 (Dkt.44).

*1339 I. Background and Procedural History

The Plaintiffs originally filed a Class Action Complaint in this case on July 13, 2001 (Dkt.l), and they filed an Amended Class Action Complaint on March 22, 2002 (Dkt.29). In their Amended Complaint, the Plaintiffs purport to bring a class action on behalf of all persons and entities who purchased stock from PSS World Medical, Inc. (“PSSI”) between October 26, 1999 and October 3, 2000, which the parties term the “Class Period” (Dkt.29, ¶ 1). The Defendants in this case are PSSI, a marketer and distributor of medical products, and certain of its executive officers and directors in their individual capacities (the “Individual Defendants”). 1 This Court entered a consolidation Order on January 14, 2002, consolidating the above-captioned case with nine other cases and appointing lead counsel (Dkt.22). However, the Court has never certified a class in this action.

In essence, the Plaintiffs allege that the Defendants’ misrepresentations during the Class Period caused PSSI’s stock to be artificially inflated (Dkt.29, ¶ 3). Ultimately, several high-ranking officers left PSSI after the company announced that its earnings for the quarter ended September 30, 2000 would in fact be below analysts’ expectations. Id. at ¶ 2. The Plaintiffs allege that the Defendants utilized several misleading and fraudulent measures in an effort to make the company’s earnings look more attractive in the short term, including the following:

1)Keeping quarters open for a period of time after the quarter had ended in order to report shipments of goods that actually occurred in the following quarter;
2) Improperly recognizing revenue on transactions where products were either not shipped or the company continued to have substantial obligations with regard to the products;
3) Failing to properly reserve for uncol-lectible accounts receivable;
4) Improperly collecting and accounting for rebates from vendors; and
5) Improperly failing to record employee bonuses.

Id. at ¶ 4. The Plaintiffs further allege that these measures constitute violations of generally accepted accounting principles (“GAAP”), had the effect of inflating the value of PSSI’s stock through misrepresentation, and that the Individual Defendants were in positions to and did in fact control such practices.

Additionally, the Plaintiffs allege that the Defendants were motivated to make misrepresentations regarding PSSI’s earnings by the company’s proposed merger with Fisher Scientific International, Inc. (“Fisher”). However, due to the income overstatements in violation of GAAP, the Plaintiffs claim Fisher terminated the merger agreement. Id. at ¶ 14. Then, following the company’s restatement of earnings on September 30, 2000, the Plaintiffs allege that PSSI’s stock value drastically declined. Id.

More specifically, the Plaintiffs provide allegations of the exact statements they contend were false and misleading at pages 10-25 of the Amended Complaint. These allegedly false and misleading statements, and the Defendants’ allegedly *1340 fraudulent course of conduct, can be briefly summarized as follows:

1. An October 26, 1999 press release announcing that PSSI was reporting “record results” in the form of revenue and profit increases, as well as a Form 10-Q filed with the SEC for the quarter ending September 30, 1999 which were false and misleading in that they improperly recognized revenue not earned during the quarter and materially overstated revenue and income for the quarter, in violation of GAAP.
2. A January 24, 2000 press release announcing the company’s results for the quarter ending December 31, 1999 and a Form 10-Q filed with the ■ SEC on February 14, 2000 reporting the same results, both of which were false and misleading in that they improperly recognized revenue on transactions, overstated PSSI’s income, failed to provide for uncollectible receivables, recognized contingent income, otherwise violated GAAP, and failed to acknowledge that the company’s worse than expected results were caused by a deterioration of business.
3. A June 22, 2000 press release announcing fiscal 2000 year-end results showing an increase in net sales and income as well as the definitive merger with Fisher and a Form 10-K filed with the SEC on June 23, 2000 reporting the same results. These statements were materially false and misleading in that they again inflated the company’s revenue, improperly failed to account for uncollectible receivables from customers in dire financial condition, improperly recognized contingent income, and understated PSSI’s net loss for fiscal year 2000. Additionally, the press release was false and misleading because it concealed the fact that the merger with Fisher was based on the above fraudulent income reports for fiscal 2000. Due to the non-disclosure of material facts, Plaintiffs allege that the investment community falsely relied on PSSI’s ability to merge with Fisher, thus further inflating the value of PSSI’s stock.
4.An August 8, 2000 press release reporting financial results for the quarter ending June 30, 2000 announcing that sales had increased and the financial requirements of the merger agreement with Fisher had been met, causing Fisher to issue a similar press release, and an August 10, 2000 Form 10-Q in which PSSI reported the same financial results. The Plaintiffs claim these documents were false and misleading because the true financial results of PSSI that were required as part of the merger agreement were not reflected, operating and net income were inflated based on PSSI’s subsequent restatement of March 31, 2001, revenue was again contingent and improperly recognized, income was overstated, extensive uncollectible receivables were not accurately reported, and accruals of bonuses were not reported, all in violation of GAAP. Ultimately, Plaintiffs allege that these financial results were ultimately restated to reduce sales, income and accounts receivable. As a result of Fisher’s investigation of PSSI’s books, Plaintiffs allege that the merger agreement was terminated in September 2000 and PSSI’s stock value subsequently drastically declined.

Id. at ¶¶ 26-49. The Plaintiffs then go on to allege that at the end of the class period, officers of PSSI resigned and the company’s earnings were subsequently re *1341 stated, substantially reducing the company’s net income and causing the stock value to drastically decline. Id. at ¶¶ 50-54.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Jiangbo Pharmaceuticals, Inc.
884 F. Supp. 2d 1243 (S.D. Florida, 2012)
In Re Pegasus Wireless Corp. Securities Litigation
657 F. Supp. 2d 1320 (S.D. Florida, 2009)
Lormand v. US Unwired, Inc.
565 F.3d 228 (Fifth Circuit, 2009)
Edward J. Goodman Life Income Trust v. Jabil Circuit, Inc.
560 F. Supp. 2d 1221 (M.D. Florida, 2008)
In Re Coca-Cola Enterprises Inc. Securities Litigation
510 F. Supp. 2d 1187 (N.D. Georgia, 2007)
In re Catalina Marketing Corp. Securities Litigation
225 F.R.D. 684 (M.D. Florida, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
250 F. Supp. 2d 1335, 2002 U.S. Dist. LEXIS 14887, 2002 WL 32054710, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-pss-world-medical-inc-securities-litigation-flmd-2002.